George Rusakovich has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Thrombotic Events in Patients with Myocardial Infarction: Proteomic Analysis of Platelets and Plasma Combined with Hemostasis Assessment

    by A. S. Anisimova, G. I. Rusakovich, E. V. Maryukhnich, O. I. Ivanova, A. I. Kalinskaya, A. K. Elizarova, O. A. Dukhin, E. L. Kordzaya, A. E. Bugrova, A. G. Brzhozovskiy, et al.

    Aim   To determine factors associated with an increased risk of thrombotic complications during antiplatelet therapy in patients with acute myocardial infarction (AMI) based on a study of the parameters of hemostasis functional activity, as well as the proteomic composition of blood plasma and platelets. Material and methods A single-center prospective clinical study assessed hemostasis parameters and quantified the plasma and platelet proteome before and after dual antiplatelet therapy (DAPT) in 98 AMI patients. Clinical data on thrombotic complications that occurred during the follow-up period were collected for 12 months after the inclusion into the study. A statistical analysis of the collected data was performed, and the proteins were identified whose concentrations were associated with an increased risk of late thrombotic complications. Results The comparative analysis of patient groups with and without thrombotic complications revealed statistically significant differences in the concentrations of several proteins. The univariate regression analysis identified proteins associated with an increased risk of thrombotic complications in the long term. Statistically significant factors with a 95% confidence interval different from 0 were the concentrations of platelet proteins, including von Willebrand factor, complement component C8 β-chain, and cation-independent mannose-6 phosphate receptor. Conclusion The study identified proteins whose concentrations were associated with an increased risk of thrombotic complications in AMI patients taking DAPT. Before implementing these findings in clinical practice, a randomized prospective study should be performed for validation of the study results.

  • Open Access

    Cytokine Profiling of Plasma and Atherosclerotic Plaques in Patients Undergoing Carotid Endarterectomy

    by Daria Potashnikova, Elena Maryukhnich, Daria Vorobyeva, George Rusakovich, Alexey Komissarov, Anna Tvorogova, Vladimir Gontarenko, Elena Vasilieva

    Atherosclerotic plaques are sites of chronic inflammation with diverse cell contents and complex immune signaling. Plaque progression and destabilization are driven by the infiltration of immune cells and the cytokines that mediate their interactions. Here, we attempted to compare the systemic cytokine profiles in the blood plasma of patients with atherosclerosis and the local cytokine production, using ex vivo plaque explants from the same patients. The developed method of 41-plex xMAP data normalization allowed us to differentiate twenty-two cytokines produced by the plaque that were not readily detectable in free circulation and six cytokines elevated in blood plasma that may have other sources than atherosclerotic plaque. To verify the xMAP data on the putative atherogenesis-driving chemokines MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), and fractalkine (CX3CL1), qPCR was performed. The MIP1A (CCL3), MIP1B (CCL4), FKN (CX3CL1), and MCP1 (CCL2) genes were expressed at high levels in the plaques, whereas RANTES (CCL5) was almost absent. The expression patterns of the chemokines were restricted to the plaque cell types: the MCP1 (CCL2) gene was predominantly expressed in endothelial cells and monocytes/macrophages, MIP1A (CCL3) in monocytes/macrophages, and MIP1B (CCL4) in monocytes/macrophages and T cells. RANTES (CCL5) was restricted to T cells, while FKN (CX3CL1) was not differentially expressed. Taken together, our data indicate a plaque-specific cytokine production profile that may be a useful tool in atherosclerosis studies.


  • Open Access

    Targeted Blood Plasma Proteomics and Hemostasis Assessment of Post COVID-19 Patients with Acute Myocardial Infarction

    by Anna Kalinskaya, Daria Vorobyeva, George Rusakovich, Elena Maryukhnich, Alexandra Anisimova, Oleg Dukhin, Antonina Elizarova, Oxana Ivanova, Anna Bugrova, Alexander Brzhozovskiy, et al.

    The molecular mechanisms underlying cardiovascular complications after the SARS-CoV-2 infection remain unknown. The goal of our study was to analyze the features of blood coagulation, platelet aggregation, and plasma proteomics in COVID-19 convalescents with AMI. The study included 66 AMI patients and 58 healthy volunteers. The groups were divided according to the anti-N IgG levels (AMI post-COVID (n = 44), AMI control (n = 22), control post-COVID (n = 31), and control (n = 27)). All participants underwent rotational thromboelastometry, thrombodynamics, impedance aggregometry, and blood plasma proteomics analysis. Both AMI groups of patients demonstrated higher values of clot growth rates, thrombus size and density, as well as the elevated levels of components of the complement system, proteins modifying the state of endothelium, acute-phase and procoagulant proteins. In comparison with AMI control, AMI post-COVID patients demonstrated decreased levels of proteins connected to inflammation and hemostasis (lipopolysaccharide-binding protein, C4b-binding protein alpha-chain, plasma protease C1 inhibitor, fibrinogen beta-chain, vitamin K-dependent protein S), and altered correlations between inflammation and fibrinolysis. A new finding is that AMI post-COVID patients opposite the AMI control group, are characterized by a less noticeable growth of acute-phase proteins and hemostatic markers that could be explained by prolonged immune system alteration after COVID-19.


  • The state of platelet and plasma hemostasis as a predictor of coronary blood flow in patients with acute myocardial infarction

    by O. A. Duhin, A. I. Kalinskaya, G. I. Rusakovich, A. S. Anisimova, J. E. Netylko, P. A. Polyakov, E. Yu. Vasilieva, A. V. Shpektor

    Aim      To study the relationship of the platelet function and plasma homeostasis with the blood flow in the infarct-related artery (IRA) and with the course of acute myocardial infarction (AMI). Material and methods  This study included 93 patients with AMI (75 patients with ST-elevation AMI and 18 patients without ST segment elevation). 63 patients had TIMI 0-1 blood flow in the IRA and 30 patients had TIMI 2–3. Rotational thromboelastometry, impedance aggregometry, the endothelium-dependent vasodilation (EDVD) test, and the thrombodynamics test were performed for all patients. The primary clinical endpoint included the totality of in-hospital complications of AMI, and the secondary endpoint included the totality of out-of-hospital complications of AMI. Major bleedings (BARC 3-5) and minor bleedings (BARC 1-2) were evaluated separately. Results Patients with IRA TIMI 0–1 flow were characterized by a shorter blood clotting time (BCT), larger thrombus size and density, more intense platelet aggregation induced by arachidonic acid and ADP, and lower values of the EDVD test. It was found that the parameters of platelet aggregation induced by arachidonic acid (AUC Asa) in combination with BCT allowed assessment of the severity of IRA blood flow disorder (sensitivity 76 %, specificity 71 %) in patients with AMI, regardless of the presence of ST segment elevation on the ECG. In addition, the incidence of the primary endpoint was greater in patients with IRA TIMI 0–1 flow (41.3% and 16.7%, respectively; p=0.015). In patients with TIMI 2–3 flow in the long-term period of the disease, the incidence of minor bleedings was significantly higher (8.5% and 30.4 %, respectively; p=0.045). Conclusion      Compared to patients with preserved blood flow, patients with AMI and IRA TIMI 0–1 flow are characterized by endothelial dysfunction and more intense processes of thrombogenesis and platelet aggregation. It has been shown for the first time that the combination of two simple criteria for assessing hemostasis (AUC Asa; BCT) allows assessment of the degree of IRA blood flow disorder in patients with AMI.